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Introduction
We will examine the unique interconnectedness of research and practice in
relationship to perimenopause (women’s normal life phase that is the transition between
reproductive adulthood and menopause). This introduction will provide an annotated
narrative of the personal and medical-political aspects of our discovery that
perimenopause is a time of high and chaotic estrogen levels, rather than declining levels,
as the current paradigm insists. That story will be followed by two aspects of the pilot
research we began in an effort to transform knowledge into something that would assist
those clinicians seeing distressed women and feeling at a loss to help them to understand
and deal with a difficult time in perimenopause.
The story begins when the first author began to wake at night sweating and
remain sleepless, had continuous sore and swollen breasts and dreamed that she was
pregnant (Prior, 1998a). As a medical specialist in endocrinology, she knew that her
symptoms could not be caused by low estrogen levels. She, like other physicians, had
been taught that dropping estrogen levels occurred before menopause (one year without a
period). She became angry that the “received wisdom” was opposite to her experience—
she knew that she, like many women she had struggled to treat, was face to face with
higher estradiol levels.
These strong feelings motivated the first author to carefully and systematically
explore the medical literature related to the hormonal and experience changes of
perimenopause (Prior, 1998b). A meta-analysis of published studies that compared,
within centre, premenopausal and perimenopausal women’s serum estradiol levels
showed average levels 30 percent higher than in younger women (Prior, 1998b).
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2Meanwhile, the hypothesis that estrogen levels are declining in perimenopause
(Burger et al., 1995) was sufficiently strong that seasoned clinical investigators could not
“see” the very high estradiol levels that they, themselves, documented in an excellent
population-based study (Prior, Barr, & Vigna, 1996). A further review by the first author
documented clearly that ovulation disturbances and lower progesterone levels are also
common in perimenopause (Prior, 2002). Finally, in perimenopause, estrogen levels are
not subject to the usual feedback controls and therefore are unlikely to be suppressible
with estrogen therapy (Prior, 1998b). Because progesterone physiologically
counterbalances the effects of estrogen, these hormonal changes of perimenopause
suggested to us that progesterone, rather than estrogen, would be an appropriate therapy
for symptomatic perimenopausal women.
A further practical problem for health care providers (HCP) and patients relates to
the diagnosis of perimenopause. The higher estrogen and lower progesterone levels in
midlife women occur when they are still cycling regularly (Santoro, Rosenberg, Adel, &
Skurnick, 1996) and would therefore not yet meet the irregular-cycle criterion for
entering the “menopausal transition” (the official name for perimenopause) (Soules et al.,
2001). Irregular cycles are known to begin, on average, at 47.5 years in the population
(McKinlay, Brambilla, & Posner, 1992) .
A further literature review documented a number of troublesome experiences
associated with perimenopause—heavy flow, cyclic night sweats, sore breasts, mood
swings, fluid retention, weight gain and sleep disturbances (Prior, 1998b). We followed
this with analysis of Daily Perimenopause Diary© records showing that cyclic night
sweats and breast tenderness occurred in regularly menstruating midlife women (Hale,
Hitchcock, Williams, Vigna, & Prior, 2003). Reasons for most of these perimenopause-
associated symptoms remain poorly understood, but abnormally heavy menstrual flow is
caused by higher estrogen levels and lower progesterone effects (Moen, Kahn, Bjerve, &
Halvorsen, 2004).
The conflict of new knowledge with an existing paradigm is common in science
(Kuhn, 1970). Therefore the contentious issue about whether estrogen is high or dropping
in perimenopause could be dismissed as an intellectual argument, or as an irrelevant
conflict between physician/scientists working from different perspectives (Prior, 2005).
However, as a group of women researchers, we could see the relevance of this new
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3science to the health and well-being of midlife women. This is especially so because the
current therapy recommendations for symptomatic midlife women are estrogen therapy
or oral contraceptives (containing supraphysiological estrogen levels even though they,
with respect to the earlier Pill, are called “low dose”) ( Greendale & Greendale, 2002).
Our goal now became to develop safe and effective education and treatment for
the approximately 20 percent of women who are symptomatic in perimenopause
(Kaufert, Gilbert, & Hassard, 1988). Despite the current baby boom demographic, no
perimenopausal therapies have been proven effective in randomized, double-blind,
placebo-controlled trials. Low dose oral contraceptives (OC) make unexpected bleeding
worse for the first three cycles and only in the fourth through the sixth cycles do they
help reduce bleeding for perimenopausal women with heavy flow (Casper, Dodin, Reid,
& Study Investigators, 1997). Furthermore, OC therapy did not significantly improve
quality of life nor hot flushes compared with placebo (Casper et al., 1997). We know of
no randomized controlled trials showing that estrogen/progestin is effective for hot
flushes in perimenopausal as opposed to menopausal women.
Based on this new knowledge of the physiology of perimenopause (Prior, 1998b),
we designed a placebo-controlled study comparing the recommended therapy, low dose
OC, against progesterone therapy prescribed for the last 14 days of the menstrual cycle.
We designed the progesterone therapy to be in a physiological dose (300 mg) that keeps
the serum progesterone level in the luteal phase range for 24 hours since it can only be
given at bedtime because of its sleep side effects (Friess, Tagaya, Trachsel, Holsboer, &
Rupprecht, 1997). This would amount to “luteal phase replacement therapy,” for those
with anovulatory cycles. It would also supplement normal levels of progesterone to
counterbalance the effects of the high estrogen levels or would augment short luteal
phases if these were present.
We wrote and submitted a proposal for a double-blind, placebo-controlled
randomized controlled three-arm study (low dose oral contraceptive, cyclic progesterone
therapy, double placebo) for symptomatic women in early perimenopause. The trial was
to last three years. We included a placebo arm, not just because this is the ideal trial
design, but also because the natural history of experiences and symptoms was not known.
We submitted our proposal to a Women’s Health competition funded by a Medical
Research Council of Canada-Industry Liaison grant. It was rejected with comments that
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4OC had been proven successful in treatment of symptomatic perimenopause and that we
were wrong about that study (Casper et al., 1997). We revised our proposal according to
reviewers’ comments and resubmitted the proposal to the Canadian Institutes of Health
Research. With our second rejection that contained similar content concerns plus
technical randomized controlled trial design corrections, we revised again and re-
submitted. The third rejection, that received an even lower score than the first, caused us
to give up trying. With the wisdom of hindsight, it is clear that the content reviewers of
our grant proposal believed that the OC trial in perimenopause was successful (Casper et
al., 1997). They held this understanding because of their hypothesis about
perimenopause-as-dropping-estrogen and also because the pharmaceutical company
sponsoring the trial and analyzing the trial data was not forced by the publishing journal
nor the reviewers to state the statistical results of OC versus placebo in the abstract.
Furthermore, figures in the published paper suggested that OC had beneficial effects
although statistical significance was not met (Rowe & Allen, 2006; Casper et al., 1997).
The historical, demographic context in which we were making these observations
and getting these rejected research applications was highly relevant to us. In 2000,
approximately 19 percent of Canadian women were ages 40-55 and thus likely in
perimenopause. We knew that 20 percent of perimenopausal women were symptomatic
(Kaufert et al., 1988). We also knew that the hysterectomy rate in British Columbia was
4.1/1000 adult women/year—it varied from 2.4 in the metropolitan region with a medical
school, to 6.7/1000/yr in a remote, rural region of the province (Ministry of Health,
Ministry Responsible for Seniors, & Women's Health Bureau, 2000). The vast majority
of hysterectomies are known to be performed for benign conditions (Maresh et al., 2002)
and the average age at hysterectomy is between ages 44-46. This is before irregular
cycles usually begin and thus before a diagnosis of perimenopause is made by
conventional criteria (Soules et al., 2001)—women with hysterectomy would thus have
no explanation for heavy flow and major surgery.
As women who were known in the region for our research and teaching about
perimenopause and women’s health, we were personally confronted with the legitimate
and often urgent concerns of midlife women. They e-mailed, telephoned and faxed their
questions and requests; about 10 women per week asked for our advice and help. We
struggled to respond. Although, for the previous decade, the first author had been referred
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5and provided consultation care for the most symptomatic midlife women in the province,
around this time, increasing academic demands caused her to close her one-day-a-week
clinical practice to new patients.
In 2002 we founded the Centre for Menstrual Cycle and Ovulation Research and,
in 2003 launched the CeMCOR Web site (www.cemcor.ubc.ca). Some of the first articles
we posted there gave information about and self-help tools to aid perimenopausal women
and their health care providers. This helped to relieve the responsibility to provide
personal information for symptomatic perimenopausal women, but we were left with no
scientific data on which to base our recommendations. We therefore decided to do a more
practice-based investigation. We planned a long-distance consultation for women that
would assist HCP to provide appropriate local care. We were already in touch with the
James Bay Community Project in a city of about 100,000 located approximately three
hours away by road and ferry. The Project was trying to start a midlife women’s health
programme as part of their medical clinic and asked for our support and advice. (This
midlife programme never materialized for irrelevant reasons.) Therefore we began a pilot
project that would at the same time be a long distance physician specialist consultation to
HCP and also provide direct education and support for perimenopausal women.
We realized that we currently lacked data on the demographic, social, physical
and medical characteristics of symptomatic women seeking assistance from their HCP
about perimenopause, and that accurate information, support and learning to keep self-
records would assist such women. We also needed to know what concerns HCP may
have about their own assessment and management of symptomatic midlife women.
Finally, we didn’t know whether a specialist consultation for a specific patient would
assist that HCP and, in turn, provide better care for his/her symptomatic perimenopausal
patients.
Having described the course of this research from personal experience to new
knowledge, to a venture into clinical practice research, the next two parts of this study
will describe our preliminary research.
Part 1: Health Care Providers’ Perceived Perimenopausal Management Problems
Primary health care providers (HCP) are nurse clinicians, general practitioners or
family physicians that deliver primary medical care. There has long been considerable
uncertainty about therapy for midlife women (Hemminki, Topo, Malin, & Kangas, 1993;
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6Barlow, Brockie, & Rees, 1991; Larcos, 1996) that consensus statements have
unsuccessfully attempted to alleviate (Wathen, Feig, Feightner, Abramson, & Cheung,
2004). Because perimenopausal women are commonly called (and call themselves)
“menopausal,” and are understood to have dropping or low estrogen levels, they, like
women one year beyond the final period (who are truly menopausal), are commonly
treated with “estrogen replacement.” Concerns about such treatment increased following
publication of the results showing more harm than benefit from randomized controlled
trials of hormone therapy in asymptomatic menopausal women (Writing Group for the
Women's Health Initiative Investigators, 2002; Anderson et al., 2004). Would the results
apply to perimenopause? The purpose of this HCP survey was to learn what concerns and
symptoms midlife women brought that these professionals found most difficult to
address.
Methods
A clinical scientist interviewed 30 different HCP (29 family or general physicians
and one nurse clinician) in person or over the telephone. HCP were a convenience sample
from two urban areas in coastal southern British Columbia. Sixteen HCP from one city
had referred symptomatic perimenopausal women to the Pilot Perimenopause
Experiences Project (Part 2). The remaining HCP from the larger city had referred
patients to a single specialist within the preceding year. No consenting HCP was
excluded; all available interview data were analyzed. HCP gave informed consent to this
study that was approved by the Behavioural Research Ethics Board of the University of
British Columbia.
The interview consisted of an open-ended question: “What kinds of problems or
concerns do your midlife/perimenopausal women patients have that currently pose the
most difficulty for you?” All answers were written on a research form verbatim. Sixteen
of the HCP were asked the same question in a second interview an average of 11 weeks
later to assess test-retest reliability of their responses.
We used descriptive statistics to analyze the interview responses of the HCP. For
the purpose of analysis, the thirty-two test-retest interviews from the 16 HCP who were
interviewed twice were each considered as separate interviews in tabulating the
frequency of HCP perimenopausal concerns—this gave us a total of 46 interviews in the
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730 HCP. Three independent scientists (two with an M.D. and one with a Ph.D.) reviewed
these responses and grouped them into categories. These three sets of categories were
then compared and sixteen domains identified. Differences were resolved by consensus
resulting in eleven categories. Test-retest responses for the 16 physicians were analyzed
using these 11 categories. Further, the gender of the HCP was evaluated for differences in
frequency of categories by gender.
Results
HCP included 16 women and 14 men equally distributed between the two cities.
The midlife/perimenopausal “problems or concerns” they identified were highly varied
and, in their own words, included the following: “difficulty coping,” “a lot of
depression,” “periods going wacky,” “trouble coping with stress,” “not responding to
hormones,” “anxiety about bone,” “mood swings,” “hot flushes/night sweats,” “sleep
disturbances,” “sexual dysfunction,” “anxiety,” “questions about hormone therapy,” and
“osteoporosis.” The eleven condensed categories are shown in Table 11. A frequency
distribution of these categories is illustrated in Figure 11. Seventy-six percent of HCP
interviews mentioned mood symptoms; over half suggested problems treating hot flushes
and night sweats in midlife women, and about half reported sleep problems. Over 45
percent of HCP interviews mentioned that questions about when to use hormone therapy
were problematic for them. Menstrual cycle problems such as menorrhagia were difficult
for only 30 percent, and high estrogen symptoms were reported as problematic for only
18 percent.
The test-retest interviews were conducted with 16 HCP an average of 11 (range
five to 16) weeks apart. Results (Table 21) showed that a quarter of the repeat interviews
included none of the initial concerns of that HCP. Another quarter repeated only one
previously mentioned concern, and 44 percent mentioned two of the same categories of
concern at both interviews.
Gender was equally balanced among the HCP; and men and women contributed
equally to the majority of the 11 domains of perimenopausal concerns (for example, 88
percent of women and 86 percent of men mentioned mood swings). However, 75 percent
of women, but only 36 percent of men HCP identified vasomotor symptoms as
problematic. Management of sleep disturbances among perimenopausal women likewise
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8concerned 63 percent of the women but only 36 percent of men HCP. These gender-
related differences, although probably important, did not reach statistical significance in
this small sample.
Discussion
Results of this small survey of HCP perimenopausal management concerns show
11 domains that they find difficult. The most prominent HCP concern was emotional
lability (mood swings) that others have found to be prominent in symptomatic women
ages 40-55 who visit their general practitioner (Barlow et al., 1991). “Psychogenic
symptoms,” however, had a frequency of only 2.3 percent in the wider clinical practice
population of women ages 40-69 who were not seeing their physician with
perimenopausal or menopausal concerns (Barlow et al., 1991).
Vasomotor symptoms (VMS) were also a common HCP concern. Because most
HCP believe that low estrogen levels cause VMS, their occurrence in menstruating
women was confusing. Although oral estrogen is highly effective for VMS in
menopausal women based on a meta-analysis of controlled trials (MacLennan, Lester, &
Moore, 2001), a single available controlled trial of 20 mg ethinyl estradiol with progestin
in an oral contraceptive did not significantly improve VMS in symptomatic
perimenopausal women with heavy flow (Casper et al., 1997). Higher estrogen-related
symptoms other than abnormal flow (premenstrual mood changes, breast tenderness and
weight gain) were mentioned by 18 percent of HCP. About 25 percent of HCP interviews
mentioned decreased libido and vaginal dryness as management concerns in
perimenopause. These are more commonly understood to occur in women a year beyond
their final period, although they are also reported in perimenopause (Gold et al., 2000).
Mechanism for these is not clear in perimenopause when estrogen levels are higher
(Santoro et al., 1996; Prior, 1998b) and testosterone levels are unchanged (Burger et al.,
1995). Given lack of a pathophysiological understanding, it is no wonder that treatment
for low sexual interest or vaginal discomfort is problematic for HCP. Although only 34
percent of these HCP interviews identified menstrual cycle and flow problems as difficult
to manage in perimenopause, another practice survey found that 51 percent of women
ages 40-44 and 42 percent ages 45-49 who reported seeing their practitioner for
“menopause” had irregular or heavy flow as a problem (Barlow et al., 1991).
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9Vasomotor symptoms and sleep problems were mentioned more frequently in
interviews with women than with men HCP. We can only speculate that this might be
because perimenopausal women didn’t feel as comfortable discussing these issues with
men HCP, because women HCP could empathize and thus the issues were more
prominent for them, or for unknown reasons. These data, however, reinforce the need for
a gender lens in any women’s health research (1984).
This survey certainly identifies the needs that HCP feel for safe and effective,
evidence-based therapies for perimenopause management. That these HCP management
concerns are highly variable from month to month suggests pleomorphic issues that
perimenopausal women may experience (Prior, 1998b), or may simply indicate the
variability in symptoms of the last patients these HCP saw. As one woman HCP
complained ruefully, “My biggest problem with perimenopausal women’s concerns is
their expectation that I can fix it!”
Part 2: The Pilot Perimenopause Experiences Project
The clinical and geographical context in which this pilot field study began is a
province in Canada with a population of about 4.5 million people and a southern, urban
concentration of both population and specialist physicians. Few endocrinologists
specialize in issues related to perimenopause—gynecologists are considered experts in
women’s reproduction, but their training is surgical. Current gynecology texts do not
mention, define nor provide research evidence about perimenopause, but rather
concentrate on (post)menopause. Gynecology referral for heavy flow, hot flushes or
mood swings commonly leads to therapy with oral contraceptives or estrogen (Hemminki
et al., 1993), and when these therapies fail, to hysterectomy. Hysterectomy is costly both
for women (in life-disruption and lost productivity) and for the publicly funded universal
Canadian health care system that is currently under stress. Perimenopausal high estrogen
levels, in addition to causing heavy flow (Moen et al., 2004), amplify the social stress
(Kirschbaum et al., 1996; Kirschbaum et al., 1996) of changing reproductive status in a
culture that places value on women’s youth and beauty (Page, 1994).
Having applied to perform a randomized controlled trial and not achieving
funding, few research options to learn the most effective and safe therapy for
symptomatic perimenopausal women were available to us. However, a donor presented
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CeMCOR with the opportunity to start this field pilot study of a long distance
perimenopause consultation to HCP and women. Although most telehealth projects
include significant technological investment (Schlachta-Fairchild, 2001), we elected to
first establish the effectiveness of long distance intervention before seeking financial
support for major technology utilization.
A one-year pilot study began in 2003 to provide long distance endocrinology
consultation to women and HCP in Victoria by a clinician-scientist in Vancouver who
had clinical, research and personal experience in perimenopause (Prior, 1998a). The
mature objectives of this project were: 1) To determine the feasibility of perimenopausal
long distance consultation; 2) To determine whether the consultation decreased
perimenopausal interference with each woman’s activities; and 3) To determine whether
the long distance consultation improved HCP self-assessed competence in management
of symptomatic perimenopausal women.
The purposes of the second section of this paper are to describe the design,
practical organization and baseline data on women and HCP who joined this pilot field
study.
Methods
This feasibility project was conducted in partnership with the James Bay
Community Project (JBCP) in Victoria. James Bay is a residential neighborhood (75%
rental housing) of 11,000 within the small city of Victoria in proximity to the city centre
and the provincial legislature. The JBCP that began in 1971 provides a wide range of
community services (pre-school, adolescent, seniors’ programmes, and a lending library)
as well as a primary care clinic. A Community Advisory Council was formed from
committed local women (including both a participant and a HCP representative), the
research nurse (when hired) and researchers from Vancouver. This group initially met
monthly and then quarterly. A local research nurse coordinator was hired, and
recruitment of HCP and their referred patients started in June 2003 following ethics
approvals at the University of British Columbia.
HCP were recruited to the project in two ways, through an initial letter containing
an informational brochure followed by a personal meeting with the nurse, or because
symptomatic patients requested their participation. Each participating woman required a
10
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referring HCP because the primary responsibility for her health care and prescriptions
remained with her HCP—the distance consultant never personally interviewed nor
examined her.
Data (described below) were collected using paper forms that were photocopied
and sent by postal mail or collected in person during quarterly visits by the Vancouver
researchers. Consultation letters to HCP and woman participants were sent as email
attachments in password-encrypted zip files to the nurse coordinator who printed and
delivered them in Victoria.
The timeline for HCP participants in the project is shown in Figure 2A1. HCP
who signed consent were interviewed at baseline by telephone or in person by the
consultant. The interview used a structured format to assess the problems HCP have in
managing perimenopausal women (part one of this paper), and their approach to two
clinical scenarios. Part way through the pilot study we began asking HCP to rate their
clinical competence in the management of highly symptomatic perimenopausal women
using a 1-10 graphical rating scale (Figure 3A1). Each HCP completed a referral letter for
each woman that included, as well as identifying information, major problems for which
they sought advice, a brief past, social and allergy, medical history, and a list of all
medications. In addition they assessed each woman’s degree of social support. They were
specifically invited to refer only symptomatic perimenopausal patients. To be eligible,
these would be patients they would normally refer for specialist care. The HCP received a
consultation letter concerning each referred patient about three months after she joined
the study.
The timeline of the project for each symptomatic perimenopausal woman is
shown in Figure 2B1. Referred women met with the nurse coordinator who provided
support, answered their questions, assessed their symptoms and suitability and obtained
consent. Each woman was taught to record the Daily Perimenopause Diary© (the
Diary)(Hale et al., 2003) by viewing an instructional videotape (Prior, 1999). The Diary
incorporates quantitative basal temperature recording, which each woman recorded on
awakening—the data were analyzed quantitatively using validated least squares methods
(Prior, Vigna, Schulzer, Hall, & Bonen, 1990) to provide ovulatory status and luteal
phase length. Each woman’s day-to-day experiences, cycle information and basal
temperature on the Diary provided primary information needed by the distant consultant.
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The nurse also measured each participant’s height without shoes at full inspiration,
weight on a beam balance, waist circumference in centimetres, blood pressure and heart
rate.
Local trained volunteers worked with each woman on an interviewer-
administered questionnaire [adapted from CaMOS—(Kreiger et al., 1999)] that assessed
reproductive history, diet, habits, family history and history of fracture. In addition, the
volunteer and participant completed the Midlife Transitions Questionnaire (Prior,
unpublished) designed to assess changes in common perimenopausal experiences over
the last 3 months, her current major concern, and the degree to which mood and body
perimenopausal symptoms interfere with daily life (see the Perimenopause Interference
Instruments, Figure 3B1). Self-administered questionnaires, completed by each
participant on her own included the Rand SF-36 quality of life instrument (Hopman et al.,
2000), the Multifactorial Health Locus of Control Questionnaire (Wallston, Wallston, &
DeVellis, 1978), the Restraint Scale of the Eating Behavior Questionnaire (Stunkard &
Messick, 1985) and the Patient Health Questionnaire (Spitzer, Williams, Kroenke,
Hornyak, & McMurray, 2000). We used this latter instrument reluctantly because of its
disease focus. However we needed a validated tool to formally assess emotional
problems—Patient Health Questionnaire scores were used as descriptive data, not as
diagnostic of psychiatric disease. These data plus three cycles of Daily Perimenopause
Diary© data were all used to provide information needed for the consultation letter.
An overview of the lines of communication in this Pilot Perimenopause
Experiences Project is shown in Figure 41. Women continued to record the Daily
Perimenopause Diary© for one year following entry into the study, with the nurse
coordinator contacting them by telephone or e-mail approximately every three months to
enquire about changes in experiences, lifestyle, personal situation and therapies. At the
end of the year, each woman again met with the nurse to complete a final interviewer-
administered questionnaire, complete the Perimenopausal Interference Instrument (Figure
3B1) and to repeat the scored questionnaires (Rand SF-36, Multifactorial Health Locus of
Control, Eating Behavior Questionnaire and Patient Health Questionnaire). They were
also provided with a questionnaire designed to obtain their qualitative evaluation of the
project—this was returned anonymously.
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A computer science cooperative student worked with us to develop a custom-built
database to enter and organize this project’s data, to score the questionnaires and to
facilitate study tracking. In addition, the database provided assistance with the
preparation of consultation letters, generating parallel letters in medical and lay language
from a menu of choices in various domains (see samples in Appendices A and B). The
draft letters were then manually edited before being sent to the nurse coordinator.
Statistical analysis of the baseline pilot data from HCP and women enrolled in the
Pilot Perimenopause Experience Project was confined to descriptive measures except for
the least mean square testing of basal temperature data (Prior, Vigna, Schulzer, Hall, &
Bonen, 1990).
Results
Nine health care providers (eight family physicians and one nurse practitioner)
referred 14 symptomatic perimenopausal women and completed the year of participation.
HCP averaged 15.1 years in clinical practice. HCP for this pilot included six women and
three men. There were many HCP changes during the study so that, although 15 HCP
initially joined the study, one completely left clinical practice, one began to work as
temporary relief in different physicians’ offices and didn’t follow the referred patient, and
three HCP did not refer any women into the project. Three referred women were not
sufficiently symptomatic, or could not keep the Diary data, and three, after understanding
the requirements of the study, chose not to join. The demographic characteristics of the
eligible, participating women are shown in Table 31. All but one of these completed the
project—the woman dropping out developed new work and home responsibilities that
prevented her completing the final questionnaires.
On the referral form, HCP identified issues for which they sought consultation—
on average there were 3.1 ± 1.5 such problems for each woman. In order, from most to
least common, they were: breast tenderness, mood, irregular periods, hot flushes, heavy
flow, night sweats, low libido, dysmenorrhea, fatigue, insomnia, anxiety, vaginal dryness,
dysparunia, recurrent vaginal irritations, headaches, dizziness and spotting.
Referred women were asked to identify a single primary concern from a list of
three; half of the participating women identified hot flushes and night sweats as their
primary problem. Twenty-nine percent reported heavy or long flow and only 14 percent
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primarily complained of breast soreness. Their baseline Perimenopausal Interference
Instrument (Figure 3B1) scores were: Body Interference 5.96 ± 2.08 (range 2-9) and
Mood Interference 3.96 ± 3.10 (range 0-9).
Referred women were in different phases of perimenopause (Figure 51) (Prior,
2002) fairly evenly distributed across the Phases. One third had regular cycles
(Perimenopause Phases A & B), half had irregular cycles (Phase C), and the remainder
had skipped and infrequent cycles (in Phases D and E).
The repeatability of HCP self-assessed clinical perimenopausal competence
(Figure 3A1) was evaluated in a convenience sample of 16 HCP that included only two
of the nine from this pilot (because this tool became available after start of this study).
Self-assessed HCP competence was repeatable over a period of one to three months (r =
0.77 [n=16], t15 = 4.67; p < 0.001; mean = 6.7, range 4 to 9). Self-assessed clinical
competence tended to relate to the number of symptomatic perimenopausal women each
HCP reported evaluating each week (r = 0.34) but was not correlated with years of
medical practice (r = 0.02).
The repeatability of the Perimenopausal Interference Instrument was also assessed
by two measurements in eight women approximately 12 weeks apart. Because of the
potential for different phases of the menstrual cycle to cause different experiences, the
second assessment was in the same menstrual cycle phase as much as possible. The body
interference score was poorly repeatable (r = 0.520, P = 0.231), but the mood interference
score was stable over time (r = 0.821, P = 0.023).
Baseline Patient Health Questionnaire scores indicated that the majority of
women (57%) fit into at least one diagnostic category (1.3 ± 1.3). Further, for those
women with any classification, the average number of different ones was 2.3 ± 0.9 per
woman. The most common assessments were somatoform disturbance (29%), major
depressive symptoms (29%), anxiety disturbances (21%), and panic disorder (14%).
The Multidimensional Health Locus of Control (MHLOC) questionnaire results
indicated that all women had internal Health Locus of Control as their highest scoring
attitude. A breakdown of all women’s health locus of control scores (mean ± SEM)
showed the following distribution: powerful others (11.3 ± 4.5), internal (27.6 ± 3.6) and
chance (13.1 ± 3.8).
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Finally, HCP, although feedback is not yet complete, were enthusiastic about
what they learned about their patient(s) and perimenopause from the consultation
letter(s). A typical (anonymized) HCP consultation letter is in Appendix A1. Despite this,
preliminary follow up suggests that few HCP have followed the consultant’s suggestions
specifically about treatment with oral micronized progesterone therapy. Symptomatic
perimenopausal women reported relief after viewing the Puzzle of Perimenopause video
(Prior, 1999), and learning to keep a Daily Perimenopause Diary (Hale et al., 2003)
perhaps because they had some tools with which to learn about their experiences. They
also reported being happy to receive their letter from the consultant. (See a sample
woman’s letter without identifying information, in Appendix B1). This pilot project also
demonstrated that informative and insightful distance perimenopausal endocrinology
consultation was possible when extensive, multi-modal data were obtained through
women’s Daily Perimenopause Diaries, HCP referrals, interviewer- and self-administered
questionnaires, and the simple physical assessments by a nurse coordinator.
Discussion
This Pilot Perimenopause Experiences Project field study of distance medical
consultations to HCP and their highly symptomatic perimenopausal women patients
showed that such consultations were feasible for an experienced endocrinologist to
provide. This strategy was ethically possible because all patient care and prescription
writing responsibility remained with the local HCP. This pilot also showed that women
and HCP were willing to participate. It represented an initial practical, woman-centred
approach to deal with the confusion about the hormonal changes, time course, and lack of
evidence-based therapy for symptomatic perimenopausal women. Further, by educating
HCP about their own patients, each could learn within the context of her/his clinical
practice and thus build capacity for potentially improved perimenopausal care.
Perimenopausal women referred into this project tended to be highly educated,
with a strong internal health locus of control. This may reflect the judgment of the
referring HCP about which patients would respond best to the project, or may be a
function of self-selection by the women who were offered the project by their care
providers. One-third of the women were referred in Phases A and B of perimenopause
(Prior, 2002) and prior to any changes in menstrual cycles—these women would be
15
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dismissed as in the “late reproductive stage” and thus not yet in perimenopause according
to the most current consensus (Soules et al., 2001).
The Patient Health Questionnaire was used to help identify emotional issues for
women in the study. Somewhat surprisingly, the questionnaire identified psychiatric
diagnoses in over half of the women, predominantly with somatoform, depressive, and
anxiety related problems. It is likely that the intensity of the hormonal changes amplified
socio-cultural stresses and thus unmasked underlying personal traits. This is congruent
with the fact that mood problems were identified most commonly by HCP as difficult to
treat (part one). The only way to determine whether the issues identified by the Patient
Health Questionnaire are truly psychiatric diagnoses would be to perform a within-
woman longitudinal study that would assess whether these diagnoses changed when each
woman became less symptomatic or became menopausal. This longitudinal study is
planned.
Although we are still obtaining formal feedback from women and HCP, an
interim analysis of eight women’s results showed improvement in the Perimenopause
Interference Instrument’s mood domain (Figure 3B1). Until a randomized controlled trial
against usual care is performed, it is not possible to know whether or not this
improvement is from increased information, self-learning through Diary-keeping, the
support from the nurse coordinator and interviewers (as provided to all women in the
planned randomized controlled trial) or is from the distance consultation itself (the
randomized portion of the study).
This pilot has also revealed a number of disadvantages within this innovative field
project. The primary one is that the participation is time-consuming for perimenopausal
women who are commonly already under time stress. Another obstacle to implementation
of a full project is that assessment of the data and production of the consultation letters is
demanding—this is onerous for a volunteer specialist, especially because she does not
have the satisfaction of personal interaction with each woman and each HCP. If the
benefits for women arise primarily from interaction with the nurse coordinator, such a
service would be possible to implement as part of local health care delivery. It also
remains to be seen whether the HCP gained in clinical competence from the consultation
on their symptomatic perimenopausal patient(s). Finally, lack of availability of HCP, flux
in the clinical practice environment and the stresses for HCP of being on the front line for
16
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health care, all mean that women and projects like this encounter marked changes even
within one year.
To date, only one specialist has been involved in the project. Implementing this
project on a larger scale would need to incorporate training to expand the pool of distance
consultants. The project was greatly assisted by the experience of the nurse coordinator
who had worked for 25 years as a nurse in a remote region of the province. The
consultant also drew on her experience supervising distance medical service through
Community Health Aids in remote Alaska, as well as her practical clinical consultation
experience with about 600 of the most symptomatic perimenopausal women in the
region.
If this project is deemed successful when the final data are in, it would be
important to perform a randomized controlled trial of the distance consultation compared
with usual care and add an objective outcome of HCP visits during the year before and
the year of consultation. That planned trial would be organized by randomization at the
level of the HCP and delay of the consultation letter until that usual care HCP and her
patient have completed the study. Should a randomized controlled trial prove successful,
grant requests for public health funding for wider, rural application of distance
perimenopausal consultation could proceed.
Summary
This narrative and pilot research describe the intricate and complex connections
between science and practice. Here the personal becomes science, which becomes
medical politics played out on a stage including medical publications, harried primary
care physicians and nurses, academic centres and communities with their own
demographics and clinical characteristics. This preliminary work demonstrates that the
new science about perimenopause hormonal changes can become practical and helpful
for health care providers and for women struggling to deal with hormonal chaos as well
as the demands of their daily lives.
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Tables, figures and Appendices:
Table 1: List of the eleven major categories of perimenopausal concerns identified by
health care provider (HCP) interviews and detail of the individual issues included under
each category
Category Category Name HCP individual issues included in each category
1 Mood symptoms mood problems, mood swings, emotional lability,
anxiety, depression
2 Sleep disturbances sleep troubles, insomnia, fatigue, dizzy
3 Vasomotor symptoms
(VMS)
hot flushes/ hot flashes, night sweats, vasomotor
symptoms
4 Menstrual cycles irregular cycles, excessive bleeding, menorrhagia,
spotting
5 Bone health bone health, osteoporosis, bone density tests
6 Hormone therapy questions about progesterone, estrogen, HRT,
alternatives to hormones
7 Sexual disturbances sexual dysfunction, low sex interest, declining libido,
pain on intercourse
8 Pain headache, joint pain, myalgia
9 Stress life stress, coping, memory
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10 High estrogen signs PMS, breast tenderness, weight gain
11 Cancer risks breast cancer, endometrial cancer worries
Table 2: Results of the test-retest data from 16 health care providers, showing the
reproducibility of their concerns about perimenopausal management.
Number of times the same concern about perimenopause was mentioned by a
health care provider (HCP) on test-retest 11 ± 1 (SEM) weeks apart.
Repeat Concerns None One Two Three
Number of HCP 4 4 7 1
Percentage
of all HCP (%)
25 25 44 6
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Table 3. Demographic characteristics of the women referred into the Pilot
Perimenopause Experiences Project (n=14). Values are mean ± standard error.
Variable Mean ± SE
Age (years) 49.1 ± 3.1
BMI 27.8 ± 5.7
Waist circumference 82.7 ± 12.8 cm (n=13)
Education:
Some high school 1 (7%)
high school ± some higher education 4 (29%)
university degree 9 (64%)
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Frequency distribution of HCP concerns
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Figure 1: This frequency distribution graph shows the percentage of primary health care
providers (family or general physicians and nurse clinicians, HCP) who identified each of
the major eleven categories of perimenopausal concerns as a personal diagnostic or
management issue.
24
Journal of Interdisciplinary Feminist Thought, Vol. 2, Iss. 1 [2007], Art. 6
http://digitalcommons.salve.edu/jift/vol2/iss1/6
25
Figure 2. Study timeline for health care providers (Physician/Nurse Clinician) (A) and
referred women (Participant) (B) during the Pilot Perimenopause Experiences Project.
A.
B.
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Figure 3:
A: Health Care Provider’s self-assessed Clinical Competence in evaluation and
management of highly symptomatic perimenopausal women
Visualize a line from 0 to 10 where 0 means very low and 10 means very high
competence in the clinical assessment and care of highly symptomatic women in
perimenopause. Where on this 0 to 10 line would you consider you lie?
0 1 2 3 4 5 6 7 8 9 10
Very low competence Very high
competence competence
B: Perimenopausal Interference Instruments 
 
During the past 3 months have any of the body changes of perimenopause interfered
with your usual activities?
0 1 2 3 4 5 6 7 8 9 10
No interference Extreme Interference
During the past 3 months have any of the mood changes of perimenopause interfered
with your usual activities?
0 1 2 3 4 5 6 7 8 9 10
No interference Extreme Interference
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Figure 4. Health care delivery model for the Pilot Perimenopause Experiences Project. A
local research nurse coordinates all communications between the specialist consultant and
the participating primary health care providers and the referred perimenopausal women.
Where required, telephone conversations between the primary HCP and the specialist
consultant have been helpful.
Specialist 
Consultant 
Local Research Nurse 
Coordinator 
Patient/ 
Participant 
(woman) 
Patient/ 
Participant 
(woman) 
Patient/ 
Participant 
(woman) 
Distant 
community 
Primary Health 
Care Provider 
(HCP) 
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Figure 5. Distribution of referred women across the five Phases of Perimenopause (Prior,
2002).
Changes in
Experience 
Irregular
periods 
Final 
period Menopause
Time
2-5 years ± 3 years 1 year 
2 (15%)
1 (8%)
6 (46%)
1 (8%)
2 (15%)1 (8%)
D
C or D 
C
B or C 
BA
A B C D E
Phase
28
Journal of Interdisciplinary Feminist Thought, Vol. 2, Iss. 1 [2007], Art. 6
http://digitalcommons.salve.edu/jift/vol2/iss1/6
29
Appendix A—Sample letter to Health Care Provider:
Dear Dr. ________
Re: ________
Thank you for referring ________ to the Perimenopause Experiences Project study.
After reviewing your referral letter, three cycles of Daily Perimenopause Diary data,
her questionnaires and physical examination results, my impressions are the following:
1. Perimenopause Phase B—this is the second of five phases of the perimenopause
and is characterized by regular cycles but high estrogen levels
2. High estrogen levels related to #1
3. Mastalgia related to #1 and #2
4. Past history of menorrhagia related to #1 and #2
5. Past Endometrial Ablation Surgery related to #1, #2 and #4
6. Anxiety related to #1 and #2
7. Sleep disturbances related to #1 and #6
8. Major life stresses—in particular related to knee injury and inability to do many
things she previously did
9. She has a history compatible with anovulatory androgen excess (commonly called
PCOS). That, in my experience, often presents in perimenopause with heavy flow.
Women with this history are at increased risk for diabetes, obesity, endometrial
cancer and hypertension as well as for symptoms and signs of androgen excess.
My suggestions and plans are:
1. I think that she would benefit from cyclic oral micronized progesterone (OMP,
Prometrium®) therapy. The dose is 300 mg at bedtime days 14-27 of the cycle.
This will not only help with breast tenderness that occurs before flow but will also
improve her anxiety symptoms, help sleep and decrease her risks for endometrial
cancer. (See Cyclic Progesterone Therapy on our website: www.cemcor.ubc.ca).
2. From her questionnaires it appears that she has quite severe limitations related to
her past knee injury. She undoubtedly needs strengthening of the medial
quadriceps and the help of a physiotherapist.
3. She needs help finding an appropriate support group or a counselor who will
assist her to not feel isolated during the complex and disturbing changes of
perimenopause.
4. She is taking a very low dose of thyroid hormone. Because of the complexity of
symptoms in perimenopause it is very important to confirm that she needs thyroid
hormone and that the dose of thyroid is appropriate for her. I suggest ordering a
TSH level. It should ideally be kept between levels of 1 and 3.
5. For anxiety and mood symptoms I suggest that she needs to do some kind of
exercise. The goal would be a brisk walk (or something else) at least 30 minutes a
day. This has been shown to help depression, definitely helps bone and will
probably help with sleep. However, at present, given her knee pain, a stationary
bicycle, or swimming or something active that is not hard on her knee would need
to be substituted. She may also benefit from taking glucosamine sulfate (1500
mg/d).
6. Increased calcium from diet or supplements has been shown to help premenstrual
symptoms. Along with a multiple vitamin providing 400 IU of Vitamin D it will
also have positive effects on bone in perimenopause.
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7. I suggest that she gradually discontinue and stop DHEAS. It has androgenic
effects and there is no evidence it is of benefit for someone with intact adrenal
glands and ovaries.
8. I would check her weight and blood pressure regularly because should she have
mild anovulatory androgen excess, perimenopause can make the risks for insulin
resistance and vascular disease increase. Should she wish something to decrease
facial hair or prevent head hair loss, spironolactone in a dose of 100 mg/day is
very helpful. It is a direct and effective anti-androgen but will not decrease blood
pressure in someone in whom it is normal.
In summary, she is a previously well woman of 46 who reports a lot of disability related
to her past knee ligament injury, who is working at home and socially isolated as well as
experiencing anxiety, panic attacks, and sore breasts in early perimenopause.
I hope this is helpful to you and to her. I look forward to following ________
with you. I will review the further diaries and updates related to her over the coming
months and convey further suggestions to you through the nurse coordinator, ________.
Please feel free to contact me if you have any questions or concerns.
Sincerely,
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Appendix B—Consultation letter to symptomatic perimenopausal woman
Dear _________,
Thank you for joining the Perimenopause Experiences Project. After reviewing Dr. ___'s
referral letter, all of the questionnaires that you completed, your physical examination
results and your three cycles of Daily Perimenopause Diary data, I've come to the
following ideas about what is going on with you:
First of all, I believe that you are in Perimenopause Phase B. This is a time of regular
cycles with higher estrogen levels and often lower progesterone levels. Often flow is
heavier or may even come too early (before 21 days). For some women, this is the worst
time for sore breasts that can stay sore all month. By the end of this phase about 25% of
women will have had one or more night sweats. Often these are regular and just before
and during flow.
We don’t really know how long this phase lasts because most experts don’t call it
'perimenopause' until a woman has skipped periods. But it is really part of perimenopause
because our experiences change and our hormones have already changed.
You are experiencing high estrogen levels related to perimenopause and these are the
major reason for your breast tenderness. Although too little progesterone can also
contribute to breast tenderness, in your case all three of your cycles were normal in
progesterone level and the length of the progesterone time (luteal phase) in the cycle.
However, although normal, your progesterone level is not sufficiently high to
counterbalance the effects of your very high estrogen levels. The good news with breast
tenderness is that it gets better as you approach and finally become menopausal!
I see that you had heavy flow for which you tried MinEstrin for seven cycles without
relief. I’m glad to see that you have had improvement from the Endometrial Ablation
Surgery you had. I’m also glad that you are still getting a little spotting because having
some flow helps to orient us in perimenopause.
Anxiety appears to be a big problem for you and is a very common symptom in
perimenopause. It is made worse because high estrogen levels amplify the stress hormone
responses to usual life stresses. It is also made worse because you are presently unable to
exercise. Exercise, relaxation, support and some progesterone to help with the high
estrogen will all make anxiety symptoms (like racing heart beat, chest pain, trouble
falling asleep and panic feelings) better.
I’ve suggested to Dr. ______ that she start you on cyclic progesterone (Prometrium)
therapy in a dose of 300 mg at bedtime on days 14-27 of your cycle. That will help with
all the things that are worse premenstrually (breast tenderness, fluid retention, mood
changes) and will help you sleep. You can go to the Centre for Menstrual Cycle and
Ovulation Research website www.cemcor.ubc.ca and find a handout called “Cyclic
Progesterone Therapy.”
It appears that you are dealing with major life stresses related to your knee injury and its
interference with your daily life and activity. I have suggested to your doctor that she
refer you for physiotherapy and help in strengthening the muscle that is always weak
(medial quadriceps) when knees hurt. You need to try to get back to some easy walking,
using a rebounder, a stationary bicycle or swimming. You may also find that taking
glucosamine sulfate (500 mg three times a day) will be helpful for you.
You sound like you have a history of unwanted hair or acne, and I noted that you are now
mentioning worry about head hair loss. Women with this history are at increased risk for
diabetes and often develop heavy flow in perimenopause. If blood pressure becomes a
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problem (it is present in your family history), a medication called spironolactone will
help with that and also make the hair changes better.
I also think it is a good idea for you to find a perimenopause support group or a counselor
so you don’t feel so all alone during this confusing time.
I’ve suggested that you gradually discontinue and stop DHEAS. It is a male hormone and
a stress hormone that can make things like facial hair and head hair loss worse.
I asked Dr. ______ to order a TSH test to be sure that the dose of thyroid you are taking
is right for you. Too much can cause anxiety and jittery feelings and make things worse.
Increasing calcium to between 1500 and 2000 mg a day (from food and if needed from
calcium pills) will also help with premenstrual symptoms and with anxiety. Your body
can only use about 500 mg at a time, so spread it out during the day for best results.
Along with a multiple vitamin pill a day, calcium will also help to prevent the bone loss
that is normal in the later stages of perimenopause.
In summary, you are a basically healthy 46-year old woman who is coping with early
perimenopause and a bum knee preventing you from doing lots of things. I have faith that
cyclic progesterone therapy will help with sleep, sore breasts and over time you will feel
much better. As you learn what is going on in perimenopause, get some support and can
exercise more, you’ll start feeling like your old self again.
I look forward to following you over this year. <the nurse coordinator> will contact you 
to review things every few months and will send your diaries to me. I'll make further 
suggestions to your doctor and <the nurse coordinator>. 
Sincerely,
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